{
  "trial_id": "NCT03264131",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Informed consent and HIPAA authorization for release of personal health information obtained.",
      "label": "met"
    },
    {
      "criterion": "Age \u2265 18 years at the time of consent.",
      "label": "met"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.",
      "label": "unknown"
    },
    {
      "criterion": "Histological confirmation of biopsy-proven peripheral T-cell leukemia/lymphoma consistent with ATLL.",
      "label": "met"
    },
    {
      "criterion": "Included subtypes will be: acute, lymphomatous, and chronic unfavorable. Chronic unfavorable is defined as the chronic variant with at least one of the following:",
      "label": "unknown"
    },
    {
      "criterion": "Positive human T-lymphotropic virus-1 (HTLV-1) antibody testing with confirmatory testing via Western blot, enzyme-linked immunosorbent assay (ELISA), or molecular testing (PCR).",
      "label": "met"
    },
    {
      "criterion": "Documented negative serologic testing for human immunodeficiency virus (HIV).",
      "label": "met"
    },
    {
      "criterion": "If positive for HBV exposure or prior infection, can continue to participate in trial with prophylactic entecavir (for HBV). If positive for hepatitis c virus (HCV) exposure or active infection, can participate in trial with monitoring for liver function abnormalities.",
      "label": "unknown"
    },
    {
      "criterion": "Demonstrate adequate organ function as defined below; all screening labs to be obtained within three days prior to study treatment.",
      "label": "unknown"
    },
    {
      "criterion": "System: Renal - Calculated creatinine clearance Laboratory Value: \u2265 30 mL/min using the Cockcroft-Gault formula for subjects with creatinine levels > 2.0 x institutional ULN",
      "label": "met"
    },
    {
      "criterion": "System: Hepatic - Bilirubin Laboratory Value: \u2264 3.0 mg/dL",
      "label": "unknown"
    },
    {
      "criterion": "System: Hepatic - Aspartate aminotransferase (AST) Laboratory Value: \u2264 2.5 \u00d7 ULN",
      "label": "met"
    },
    {
      "criterion": "System: Hepatic - Alanine aminotransferase (ALT) Laboratory Value: \u2264 2.5 \u00d7 ULN",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breastfeeding.",
      "label": "triggers"
    },
    {
      "criterion": "Has a known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least five years.",
      "label": "unknown"
    },
    {
      "criterion": "Previous exposure to brentuximab vedotin (BV).",
      "label": "triggers"
    }
  ],
  "notes": "Patient has a history of CLL and large cell transformation, with recent worsening palpable lymphadenopathy. He has received multiple lines of therapy without significant response.",
  "_meta": {
    "topic_id": "8",
    "trial_id": "NCT03264131",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}